Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR 62.05
+2.93 (4.96%)
At close: Aug 29, 2025
Concord Drugs Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Cash & Equivalents | - | 2.25 | 1.76 | 0.99 | 0.65 | 0.56 | Upgrade |
Cash & Short-Term Investments | 2.25 | 2.25 | 1.76 | 0.99 | 0.65 | 0.56 | Upgrade |
Cash Growth | 27.78% | 27.78% | 77.46% | 51.99% | 15.81% | 48.62% | Upgrade |
Accounts Receivable | - | 136.05 | 198.27 | 158.1 | 228.59 | 207.28 | Upgrade |
Receivables | - | 136.05 | 198.27 | 158.1 | 228.59 | 207.28 | Upgrade |
Inventory | - | 252.69 | 229.23 | 200.65 | 174.9 | 118.72 | Upgrade |
Other Current Assets | - | 16.63 | 16.89 | 74.82 | 14.77 | 33.69 | Upgrade |
Total Current Assets | - | 407.62 | 446.15 | 434.56 | 418.91 | 360.25 | Upgrade |
Property, Plant & Equipment | - | 135.69 | 126.67 | 132.04 | 138.83 | 131.92 | Upgrade |
Long-Term Investments | - | 8 | 8.41 | 8.94 | - | - | Upgrade |
Long-Term Accounts Receivable | - | 92.93 | - | - | - | - | Upgrade |
Other Long-Term Assets | - | 7.18 | 6.84 | 6.77 | 6.71 | 6.66 | Upgrade |
Total Assets | - | 651.42 | 588.06 | 582.31 | 564.45 | 498.83 | Upgrade |
Accounts Payable | - | 76.22 | 34.38 | 52.72 | 71.79 | 31.48 | Upgrade |
Accrued Expenses | - | - | 5.37 | 6.17 | 8.81 | 27.35 | Upgrade |
Short-Term Debt | - | 158.68 | 159.49 | 142.26 | 139.52 | 92.22 | Upgrade |
Current Portion of Long-Term Debt | - | 20.51 | 9.25 | 8.27 | 7.88 | - | Upgrade |
Current Income Taxes Payable | - | 2.06 | 2.23 | 3.81 | 6.71 | 4.71 | Upgrade |
Other Current Liabilities | - | 4.33 | 2.7 | 2.91 | 1.77 | 6.6 | Upgrade |
Total Current Liabilities | - | 261.8 | 213.41 | 216.15 | 236.47 | 162.36 | Upgrade |
Long-Term Debt | - | 13.24 | 6.45 | 19.11 | 16.95 | 37.51 | Upgrade |
Long-Term Unearned Revenue | - | - | - | - | - | 3.69 | Upgrade |
Long-Term Deferred Tax Liabilities | - | 6.26 | 4.73 | 5.37 | 6.59 | 6.77 | Upgrade |
Other Long-Term Liabilities | - | 28.98 | 19.59 | 19.89 | 19.89 | 19.89 | Upgrade |
Total Liabilities | - | 310.28 | 249.89 | 265.27 | 280.85 | 231.16 | Upgrade |
Common Stock | - | 100 | 100 | 93.16 | 87.44 | 87.44 | Upgrade |
Additional Paid-In Capital | - | - | 85.89 | 70.15 | 57 | 57 | Upgrade |
Retained Earnings | - | - | 148.19 | 143.99 | 135.07 | 119.12 | Upgrade |
Comprehensive Income & Other | - | 241.14 | 4.1 | 9.75 | 4.1 | 4.1 | Upgrade |
Shareholders' Equity | 341.14 | 341.14 | 338.18 | 317.04 | 283.61 | 267.66 | Upgrade |
Total Liabilities & Equity | - | 651.42 | 588.06 | 582.31 | 564.45 | 498.83 | Upgrade |
Total Debt | 192.44 | 192.44 | 175.19 | 169.65 | 164.34 | 129.73 | Upgrade |
Net Cash (Debt) | -190.18 | -190.18 | -173.42 | -168.65 | -163.69 | -129.17 | Upgrade |
Net Cash Per Share | -18.89 | -19.23 | -17.34 | -18.11 | -18.72 | -14.77 | Upgrade |
Filing Date Shares Outstanding | 9.81 | 9.73 | 10 | 8.74 | 8.74 | 8.74 | Upgrade |
Total Common Shares Outstanding | 9.81 | 9.73 | 10 | 8.74 | 8.74 | 8.74 | Upgrade |
Working Capital | - | 145.82 | 232.74 | 218.42 | 182.44 | 197.9 | Upgrade |
Book Value Per Share | 35.08 | 35.08 | 33.82 | 36.26 | 32.44 | 30.61 | Upgrade |
Tangible Book Value | 341.14 | 341.14 | 338.18 | 317.04 | 283.61 | 267.66 | Upgrade |
Tangible Book Value Per Share | 35.08 | 35.08 | 33.82 | 36.26 | 32.44 | 30.61 | Upgrade |
Buildings | - | - | - | - | 67.6 | 67.6 | Upgrade |
Machinery | - | - | - | - | 297.22 | 278.19 | Upgrade |
Construction In Progress | - | - | - | - | 5.54 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.